{"protocolSection":{"identificationModule":{"nctId":"NCT06622070","orgStudyIdInfo":{"id":"SPY002-072-101"},"organization":{"fullName":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of SPY002-072 in Healthy Volunteers","officialTitle":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2024-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-11-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-08-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-30","studyFirstSubmitQcDate":"2024-09-30","studyFirstPostDateStruct":{"date":"2024-10-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-11-25","lastUpdatePostDateStruct":{"date":"2024-11-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spyre Therapeutics, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Altasciences Company Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":56,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"SAD Cohorts, Experimental Arm","type":"EXPERIMENTAL","description":"Participants will receive a single dose of SPY002-072 in a dose escalation format","interventionNames":["Drug: SPY002-072"]},{"label":"SAD Cohorts, Placebo Arm","type":"PLACEBO_COMPARATOR","description":"Participants will receive a single dose of placebo","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"SPY002-072","description":"Experimental","armGroupLabels":["SAD Cohorts, Experimental Arm"]},{"type":"OTHER","name":"Placebo","description":"Placebo","armGroupLabels":["SAD Cohorts, Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Treatment emergent adverse events","description":"Incidence, severity, and causal relationship of TEAEs","timeFrame":"Up to 40 weeks"}],"secondaryOutcomes":[{"measure":"Cmax","description":"Maximum concentration after single dose","timeFrame":"Up to 40 weeks"},{"measure":"t1/2","description":"Half life after single dose","timeFrame":"Up to 40 weeks"},{"measure":"Tmax","description":"Time to reach maximum concentration after single dose","timeFrame":"Up to 40 weeks"},{"measure":"ADA","description":"Incidence of anti-drug antibody after single dose","timeFrame":"Up to 40 weeks"},{"measure":"AUC","description":"Area under the curve after single dose","timeFrame":"Up to 40 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy men and women\n* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits\n\nExclusion Criteria:\n\n* Participation in more than one cohort\n* Evidence of clinically significant abnormality or disease\n* Known history of illicit drug use or drug abuse, cannabis/cannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of â‰¥ 1 unit of whole blood within 1 month prior to dosing","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Medical Director, Clinical Development","role":"CONTACT","phone":"617-651-5940","email":"Spyre_SPY002-072-101@spyre.com"}],"overallOfficials":[{"name":"Joshua Friedman, MD","affiliation":"Spyre Therapeutics","role":"STUDY_CHAIR"}],"locations":[{"facility":"Spyre Site 2","status":"NOT_YET_RECRUITING","city":"Cypress","state":"California","zip":"90630","country":"United States","contacts":[{"name":"Sammy Armado","role":"CONTACT","phone":"714-252-0700","email":"sarmado@altasciences.com"}],"geoPoint":{"lat":33.81696,"lon":-118.03729}},{"facility":"Spyre Site 1","status":"RECRUITING","city":"Montreal","state":"Quebec","zip":"H3P 3P1","country":"Canada","contacts":[{"name":"Claudia Romero de los Reyes","role":"CONTACT","phone":"450-973-3155 Ext. 113282","email":"creyes@altasciences.com"}],"geoPoint":{"lat":45.50884,"lon":-73.58781}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25","removedCountries":["Australia"]}},"hasResults":false}